A Single-Dose, Open-Label, Randomized, Four-Way Crossover Study to Assess the Dose-Proportionality of the Pharmacokinetics of Tapentadol, Given as Tamper-Resistant Tablets, in Healthy Japanese and Korean Male Subjects.

Trial Profile

A Single-Dose, Open-Label, Randomized, Four-Way Crossover Study to Assess the Dose-Proportionality of the Pharmacokinetics of Tapentadol, Given as Tamper-Resistant Tablets, in Healthy Japanese and Korean Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Tapentadol (Primary)
  • Indications Back pain; Cancer pain; Diabetic neuropathies; Musculoskeletal pain; Neuropathic pain; Pain; Postoperative pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Nov 2011 Actual initiation date changed from Mar 2011 to Feb 2011 as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top